References
- Early Breast Cancer Trialists’ Collaborative Group. 1998. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 351:1451–1467.
- Jones ME, Van Leeuwen FE, Hoogendoorn WE, Mourits MJ, Hollema H, Van Boven H, et al. 2012. Endometrial cancer survival after breast cancer in relation to tamoxifen treatment: pooled results from three countries. Breast Cancer Research 14:R91.
- Kloos I, Delaloge S, Pautier P, Di Palma M, Goupil A, Duvillard P, et al. 2002. Tamoxifen-related uterine carcinosarcomas occur under/after prolonged treatment: report of five cases and review of the literature. International Journal of Gynecological Cancer 12:496–500.
- Matsuo K, Ross MS, Bush SH, Yunokawa M, Blake EA, Takano T, et al. 2017. Tumor characteristics and survival outcomes of women with tamoxifen-related uterine carcinosarcoma. Gynecologic Oncology 144:329–335.
- Moukarzel LA, Ferrando L, Da Cruz Paula A, Brown DN, Geyer FC, Pareja F, et al. 2021. The genetic landscape of metaplastic breast cancers and uterine carcinosarcomas. Molecular Oncology 15:1024–1039.
- Nicoletti R, Lopez S, Bellone S, Cocco E, Schwab CL, Black JD, et al. 2015. T-DM1, a novel antibody-drug conjugate, is highly effective against uterine and ovarian carcinosarcomas overexpressing HER2. Clinical and Experimental Metastasis 32:29–38.
- Pezzicoli G, Moscaritolo F, Silvestris E, Silvestris F, Cormio G, Porta C, D’oronzo S. 2021. Uterine carcinosarcoma: an overview. Critical Reviews in Oncology/Hematology 163:103369.
- Raspollini MR, Susini T, Amunni G, Paglierani M, Taddei A, Marchionni M, et al. 2005. COX-2, c-KIT and HER-2/neu expression in uterine carcinosarcomas: prognostic factors or potential markers for targeted therapies? Gynecologic Oncology 96:159–167.
- Rottmann D, Snir OL, Wu X, Wong S, Hui P, Santin AD, Buza N. 2020. HER2 testing of gynecologic carcinosarcomas: tumor stratification for potential targeted therapy. Modern Pathology 33:118–127.
- Sawada M, Tsuda H, Kimura M, Okamoto S, Kita T, Kasamatsu T, et al. 2003. Different expression patterns of KIT, EGFR, and HER-2 (c-erbB-2) oncoproteins between epithelial and mesenchymal components in uterine carcinosarcoma. Cancer Science 94:986–991.